Quote of the Day: Lucentis vs. Avastin

Membership Ticker

BREAKING: Good journalism costs money.
And we need a lot of both right now. We’re short of our August goal of $163,000 in online donations, and it’s not going to get any easier next month when election noise and news will be even louder. You know what’s at stake. And you know Mother Jones is up for it. Will you pitch in now so we can do our best work?

We need to raise $163,000 before the month ends and the election noise and news get louder. You know what’s at stake. And you know Mother Jones is up for it. Please help if you can.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

I love this News of the Weird summary of this New York Times article:

Treatments for Age-Related Macular Degeneration: Lucentis ($2,000 an injection) or the equally effective Avastin (off-label: $50). Problems: (a) Lucentis thus costs Medicare (i.e., you) a bargeload of money. (b) Both drugs are made by the same company. (c) That company, somehow, for some odd reason, prefers that patients use Lucentis and therefore offers a “promotion program” (i.e., bribes) for doctors to prescribe it. (Bonus: The bribes are legal.)

Stay classy, pharmaceutical industry!